Nymox Pharmaceutical (NYMX) Reports Update And Positive Safety Data For Phase 3 NX02-0022 Reinjection Study Of NX-1207 For BPH  
11/11/2013 11:38:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HASBROUCK HEIGHTS, N.J., Nov. 11, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported a favorable update and recent Safety Monitoring Committee review of safety data for the Company's NX02-0022 reinjection study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The most recent Safety Monitoring Committee meeting found no significant safety concerns to date. Enrollment in this study at participating investigational sites across the U.S. has passed the 50% accrual level.

Help employers find you! Check out all the jobs and post your resume.